Allogeneic Stem Cell Transplantation of NiCord, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients With Hematological Malignancies

Trial Profile

Allogeneic Stem Cell Transplantation of NiCord, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients With Hematological Malignancies

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Cord blood stem cell therapy (Primary)
  • Indications Haematological malignancies
  • Focus Therapeutic Use
  • Sponsors Gamida-Cell
  • Most Recent Events

    • 01 Nov 2017 According to a Gamida Cell media release, data from this trial will be presented during the 59th Annual Meeting of the American Society for Hematology (ASH) 2017.
    • 17 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 22 May 2017 Planned End Date changed from 1 Mar 2018 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top